Modelo estratégico integral para los procesos de la salud ocupacional (SG- SST) para la empresa: Maeds Constructores SAS

Esta investigación fue desarrollada en Maeds Constructores SAS en el año 2018, una compañía de construcción que opera en la ciudad de Cali. En el caso de sus trabajadores (administrativos y operativos), enfrentan diariamente riesgos físicos y mentales ergonómicos que ponen en peligro su salud y la productividad de la empresa, esta investigación busca identificar los riesgos ergonómicos presentes en el ambiente de trabajo, su naturaleza, en otros aspectos Para esto, se utilizaron herramientas como la entrevista con 25 empleados (20 del área operativa y 5 del área administrativa) para investigar el conocimiento de los trabajadores sobre la conciencia de los riesgos presentes. Otra herramienta fue la observación dentro de la empresa para determinar las condiciones de trabajo de los empleados y su comportamiento en el desempeño de sus funciones. Entre lo que se puede encontrar en la investigación es necesario generar una mayor conciencia en el momento en que cada empleado hace su trabajo, para que puedan desarrollarlo sin preocupaciones, sin distracciones y en mejores condiciones, ubicando correctamente a los trabajadores. Sin descuidar la productividad de la empresa. Para ello, la empresa debe desarrollar un plan de gestión y seguridad que implique la ergonomía, los procedimientos claros para cada puesto, el seguimiento en la gestión operativa de la empresa y en la gestión de las oficinas y la prevención para garantizar el bienestar de todos.This research was developed in Maeds Builders sas in 2018, a construction company that operates in the city of Cali. In the case of its workers (administrative and operational), they face daily physical and mental ergonomic risks that endanger their health and the productivity of the company, this research seeks to identify the ergonomic risks present in the work environment, its nature, in other aspects For this, tools were used such as the interview with 25 employees (20 from the operational area and 5 from the administrative area) to investigate the knowledge of the workers about the awareness of the present risks. Another tool was the observation within the company to determine the working conditions of employees and their behavior in the performance of their duties. Among what can be found in the investigation is necessary to generate greater awareness at the moment in which each employee does their work, so that they can develop it without worries, without distractions and in better conditions, correctly locating the workers. Without neglecting the productivity of the company. For this, the company must develop a management and safety plan that implies ergonomics, clear procedures for each position, follow-up in the operational management of the company and in the management of the offices and prevention to guarantee the welfare of all

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication